Table 2. Multivariate Cox Proportional Hazards Regression of statin use and other characteristics with survival.
| Category | Subcategory | Relative Hazard (95% CI) | P-Value |
| Statin Use | 0.33 (0.14,0.76) | 0.009 | |
| Age (median years) | 1.07 (1.05,1.10) | <0.0001 | |
| Race | Black | 0.82 (0.47, 1.46) | 0.51 |
| Others | 1.0 (reference) | ||
| HIV Risk Group | IDU | 2.30 (1.30, 4.07) | 0.004 |
| Heterosexual | 1.50 (0.96, 2.35) | 0.08 | |
| MSM | 1.0 (reference) | ||
| CD4+ at HAART start (per 100 cell/mm3 higher increments) | 0.96 (0.84, 1.09) | 0.52 | |
| HIV-1 RNA at HAART start (per log10 higher increments) | 0.96 (0.79, 1.18) | 0.16 | |
| Hemoglobin at HAART start (per g/dL higher increments) | 0.80 (0.71, 0.90) | 0.0003 | |
| Total Cholesterol at HAART start (per 10 mg/dL higher increments) | 0.98 (0.93, 1.03 | 0.36 | |
| Year HAART started | < = 2004 | 1.20 (0.74, 2.06) | 0.50 |
| > 2004 | 1.0 (reference) | ||
| HAART Drug | NNRTI | 1.23 (0.59, 1.52) | 0.42 |
| Others | 1.0 (reference) | ||
| Prior ART | 1.37 (0.82, 2.31) | 0.23 | |
| Prior ADI | 2.24 (1.39, 3.60) | 0.001 | |
| Viral Hepatitis C Co-infection | 1.07 (0.62, 1.84) | 0.81 |
*Male vs. female sex could not be analyzed independently because of collinearity with the MSM risk group.
(Multivariate adjusted association of Statin use and each of the other variables)1 categroies are0 mg/dL increase)g/dL increase).